donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

BDX Becton Dickinson & Co

266.810
+3.120+1.18%
Close 08/15 16:00 ET
266.81000.00%
Post Mkt Price 08/15 16:28 ET
High
267.500
Open
263.080
Turnover
205.98M
Low
262.607
Pre Close
263.690
Volume
774.25K
Market Cap
76.09B
P/E(TTM)
46.00
52wk High
276.353
Shares
285.20M
P/E(Static)
38.95
52wk Low
226.903
Float Cap
75.76B
Bid/Ask %
33.33%
Historical High
276.353
Shs Float
283.96M
Volume Ratio
0.91
Historical Low
13.411
Dividend TTM
3.44
Div Yield TTM
10000
P/B
2.99
Dividend LFY
1.29%
Div Yield LFY
3747.98%
Turnover Ratio
0.27%
Amplitude
1.86%
Avg Price
266.037
Lot Size
1
Float Cap
75.76B
Bid/Ask %
33.33%
Historical High
276.353
Shs Float
283.96M
Volume Ratio
0.91
Historical Low
13.411
Dividend TTM
3.44
P/B
2.99
Dividend LFY
1.29%
Turnover Ratio
0.27%
Amplitude
1.86%
Avg Price
266.037
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company’s BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
CEO: Polen Jr., Thomas E.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...